NASDAQ:ADTX - Nasdaq - US0070258027 - Common Stock - Currency: USD
NASDAQ:ADTX (4/28/2025, 1:32:18 PM)
2.23
-0.07 (-3.04%)
The current stock price of ADTX is 2.23 USD. In the past month the price decreased by -62.69%. In the past year, price decreased by -99.99%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.58 | 337.54B | ||
AMGN | AMGEN INC | 14.17 | 151.01B | ||
GILD | GILEAD SCIENCES INC | 13.54 | 130.61B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1693.62 | 126.26B | ||
REGN | REGENERON PHARMACEUTICALS | 13.21 | 65.93B | ||
ARGX | ARGENX SE - ADR | 322.35 | 37.40B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.90B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.90B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.24B | ||
NTRA | NATERA INC | N/A | 20.42B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.37B | ||
BIIB | BIOGEN INC | 7.16 | 17.27B |
Aditxt Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations. The company develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. The company also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
ADITXT INC
737 N. Fifth Street, Suite 200
Richmond VIRGINIA 94043 US
CEO: Amro Albanna
Employees: 47
Company Website: https://aditxt.com/
Investor Relations: https://www.aditxt.com/investor-relations/
Phone: 19094880844
The current stock price of ADTX is 2.23 USD. The price decreased by -3.04% in the last trading session.
The exchange symbol of ADITXT INC is ADTX and it is listed on the Nasdaq exchange.
ADTX stock is listed on the Nasdaq exchange.
ADITXT INC (ADTX) has a market capitalization of 2.59M USD. This makes ADTX a Nano Cap stock.
ADITXT INC (ADTX) currently has 47 employees.
The Revenue of ADITXT INC (ADTX) is expected to grow by 1584.79% in the next year. Check the estimates tab for more information on the ADTX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ADTX does not pay a dividend.
ADITXT INC (ADTX) will report earnings on 2025-05-19.
ADITXT INC (ADTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-70338.18).
ChartMill assigns a fundamental rating of 1 / 10 to ADTX. ADTX may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ADTX reported a non-GAAP Earnings per Share(EPS) of -70338.18. The EPS decreased by -9344.74% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -125.54% | ||
ROE | -454.96% | ||
Debt/Equity | 0.64 |
ChartMill assigns a Buy % Consensus number of 80% to ADTX. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -2096.63% and a revenue growth 1584.79% for ADTX